TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Amphastar Pharmaceuticals ( (AMPH) ).
On October 21, 2025, Amphastar Pharmaceuticals entered into a Distribution Agreement with Nanjing Chengong Pharmaceutical to expand the distribution of its nasal powder product, BAQSIMI®, in Mainland China, Taiwan, Hong Kong, and Macau. This agreement, which includes profit sharing and regulatory responsibilities for Chengong, represents a related party transaction due to shared ownership interests, and was approved by Amphastar’s Audit Committee.
The most recent analyst rating on (AMPH) stock is a Hold with a $26.00 price target. To see the full list of analyst forecasts on Amphastar Pharmaceuticals stock, see the AMPH Stock Forecast page.
Spark’s Take on AMPH Stock
According to Spark, TipRanks’ AI Analyst, AMPH is a Neutral.
Amphastar Pharmaceuticals’ overall stock score is driven by its strong valuation and financial stability, despite challenges in revenue growth and cash flow. The technical analysis indicates a bearish trend, but the stock’s undervaluation presents potential upside. The earnings call provided mixed signals, with strategic expansions and product successes offset by competitive pressures and declining revenues.
To see Spark’s full report on AMPH stock, click here.
More about Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. is a pharmaceutical company involved in the production and distribution of nasal powder products, with a focus on expanding its market presence in the Greater China region.
Average Trading Volume: 492,743
Technical Sentiment Signal: Sell
Current Market Cap: $1.14B
For detailed information about AMPH stock, go to TipRanks’ Stock Analysis page.